Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Splenomegaly 1Primary Myelofibrosis 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Leukemia 1Head and Neck Neoplasms 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Squamous Cell 1Anus Neoplasms 1Anemia 1

Interventions

Cisplatin 39Radiotherapy 21Carboplatin 21Cetuximab 20Paclitaxel 19Docetaxel 17Radiotherapy, Intensity-Modulated 15pembrolizumab 14Fluorouracil 13Drug Therapy 10Nivolumab 8Radiation 6cemiplimab 5atezolizumab 5Panitumumab 5Oxaliplatin 5Erlotinib Hydrochloride 5Chemoradiotherapy 5Afatinib 5Surgical Procedures, Operative 4durvalumab 3Surveys and Questionnaires 3Methotrexate 3Leucovorin 3Lapatinib 3130-nm albumin-bound paclitaxel 3toripalimab 2palbociclib 2osimertinib 2dacomitinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Squamous Cell × ON 01910 × Clear all
NCT01807546 2017-06-26

Oral Rigosertib for Squamous Cell Carcinoma

Traws Pharma, Inc.

Phase 2 Completed
64 enrolled
GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Anus Neoplasms, Carcinoma, Squamous Cell, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡